Latest Astellas Pharma Inc. Stories
Focus on research and development for small molecule inhibitors of oncogenic K-Ras - the most commonly mutated oncogene in human cancers BOSTON and TOKYO, Nov.
More than 6,000 employees worldwide have already completed over 13,000 hours of volunteer service in their communities TOKYO, Nov. 4, 2014 /PRNewswire/ -- Astellas Pharma Inc.
HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds
- AIMing to establish a new treatment for ophthalmologic diseases - TOKYO, Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma Inc.
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept.
TOKYO, Aug. 8, 2014 /PRNewswire/ -- Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT"), are to join forces with Astellas Pharma Inc.
Special Patient-Focused Event Kicks Off Astellas' Fifth Annual Changing Tomorrow Day Initiative KISSIMMEE, Fla., June 11, 2014 /PRNewswire/ -- About 1,400 Astellas Pharma employees
-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S.
LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S.
- To swell, as grain or wood with water.